{
  "id": "8057c09c-aefc-424d-abfb-a9550dc87463",
  "patient_id": "fbe5991e-cd15-4cc5-8246-3bd30cdcc515",
  "encounter_id": "a7445baa-dbe6-45a0-b1f4-6f6c9ee603dc",
  "analysis_type": "Genetic Testing Recommendation",
  "input_text": "Patient: John Doe, DOB: 1980-05-15, Gender: Male\n\nChief Complaint: headache\n\nS: no previous history of headache\n\nO: No physical exam documented.\n\nA: No assessment documented.\n\nP: No plan documented.\n\n--- IMAGING & SCANS ---\n- ECG (3/24/2025): ECG For Patient\n\n--- IMAGING & SCANS ANALYSIS ---\n\n[Scan 1: ECG (2025-03-24T21:51:25.290300)]\nFile: norm.png\nDescription: ECG For Patient\nAnalysis: Okay, let\u2019s analyze this ECG tracing. Here\u2019s a detailed breakdown of what I see, incorporating observations and potential interpretations:\n\n**Overall Impression:**\n\nThe ECG appears to be of a patient with a sinus rhythm, but with some notable findings suggesting underlying cardiac pathology.  The rate is slightly elevated, and there\u2019s evidence of left ventricular hypertrophy (LVH). \n\n**Detailed Analysis:**\n\n1. **Rate:** The heart rate is approximately 90-100 bpm. It's slightly elevated, which could be due to a variety of factors.\n\n2. **Rhythm:** The rhythm is regular, indicating a consistent and coordinated heartbeat.  It's a sinus rhythm, meaning the electrical impulses are originating from the sinoatrial (SA) node, the heart's natural pacemaker.\n\n3. **P Waves:**\n   *   P waves are present and appear generally upright in leads I, II, aVL, V1, V2, V5, and V6. \n   *   The morphology of the P waves is somewhat rounded and not distinctly shaped, which could be indicative of underlying conduction abnormalities or other subtle issues.\n\n4. **PR Interval:**  The PR intervals are slightly prolonged, ranging between 0.22-0.26 seconds.  Prolonged PR intervals often suggest first-degree AV block, although it can be influenced by electrolyte imbalances or medications.\n\n5. **QRS Complexes:**\n   *   The QRS complexes are wide, ranging from 0.12-0.14 seconds. This is a significant finding.  Wide QRS complexes often indicate a delay in ventricular depolarization, which could be due to several reasons:\n        *   **Bundle Branch Block:** The morphology of the QRS complexes in leads V1 and V6 suggests a right bundle branch block (RBBB).  The Q waves are slurred, and the R wave in V6 is wider and less slurred than in V1.\n        *   **Ventricular Hypertrophy:** The wide QRS complexes could also be a consequence of left ventricular hypertrophy, which can distort the QRS waveform.\n        *   **Impulse Subtractive Pathology:**  Less commonly, it could be due to an impulse subtractive condition.\n\n6. **ST Segment and T Waves:**\n   *   **ST Segment:** The ST segments are generally isoelectric (flat) except for V4 and V5, where\n\n\n--- MEDICAL ENTITY ANALYSIS ---\n\nHISTORY: 1980-05-15, headache\nDISEASE_DISORDER: headache, cardiac pathology, left ventricular hypertrophy, LVH, conduction abnormalities, AV block, electrolyte, Bundle Branch Block, right bundle branch block, RBBB, Ventricular Hypertrophy, Impulse Subtractive Pathology\nDIAGNOSTIC_PROCEDURE: physical exam, ECG, rate, Rate, heart rate, Rhythm, rhythm, heartbeat, Waves, leads I, II, VL, PR Interval, PR intervals, PR, QRS Complexes, QRS complexes, ventricular, Q waves, R wave, ST Segment, T Waves\nDATE: 24, 2025, -03-24, 21:51:25\nLAB_VALUE: sinus, slightly elevated, 90-100 bpm, elevated, regular, upright, rounded, shaped, prolonged, 0., ., seconds, wide, delay, slurred, wider, isoelectric\nSIGN_SYMPTOM: rhythm, P, P waves, depolarization, S\nBIOLOGICAL_STRUCTURE: sino, node, 1, 5, 6, leads V1 and V6, V6, ST, ST segments, V4 and V5\nDETAILED_DESCRIPTION: atrial, SA, ,, , a, , V, , V2, V, , and V, first-degree, 1\nDISTANCE: 22, 0, 26, 12, 14",
  "recommendation": "recommended",
  "reasoning": "The patient, John Doe, presents with an ECG showing several concerning findings suggestive of underlying cardiac pathology.  Specifically, the ECG reveals a slightly elevated heart rate (90-100 bpm), evidence of left ventricular hypertrophy (LVH), slightly prolonged PR intervals (0.22-0.26 seconds), and significantly wide QRS complexes (0.12-0.14 seconds). The morphology of the QRS complexes suggests a right bundle branch block (RBBB).  These findings raise concerns for several potential conditions, including but not limited to Brugada syndrome, arrhythmogenic right ventricular cardiomyopathy (ARVC), and potentially other cardiomyopathies associated with genetic mutations affecting cardiac ion channels or structural proteins.  The literature review highlights the importance of genetic testing in diagnosing these conditions, particularly when there is a family history of sudden cardiac death or related arrhythmias. While the patient's chief complaint is a headache with no prior history, the significant cardiac abnormalities detected on ECG warrant further investigation.  The absence of a detailed physical exam and medical history limits the ability to definitively rule out other conditions, but the ECG findings alone strongly suggest the need for genetic testing to identify a potential underlying genetic cause for the observed cardiac abnormalities.  The specific genetic tests would depend on the results of further clinical evaluation and family history.  The literature also indicates that some genetic cardiomyopathies can present with subtle or non-specific symptoms initially, with cardiac manifestations becoming more prominent over time. Therefore, early genetic testing can be crucial for appropriate management and prevention of potentially life-threatening complications.",
  "confidence": "70%",
  "model_used": "Gemini-Pro",
  "retrieved_docs": [
    {
      "id": "salih-myo_txt_1",
      "contents": "Agents/circumstances to avoid: Ibuprofen in those with congestive heart failure. \nGenetic counseling \nSalih myopathy is inherited in an autosomal recessive manner. Te parents of an afected child are obligate heterozygotes (i.e., carriers of one pathogenic variant) and are asymptomatic. At conception, each sib of an afected individual has a $25\\%$ chance of being afected, a $50\\%$ chance of being an asymptomatic carrier, and a $25\\%$ chance of being unafected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for a pregnancy at increased risk are possible if the pathogenic variants in the family have been identifed. \nDiagnosis \nSuggestive Findings \nSalih myopathy should be suspected in individuals with the following clinical, laboratory, electrophysiologic, imaging, and histopathology fndings. \nClinical \n\u2022 Muscle weakness manifesting during the neonatal period or in early infancy   \n\u2022 Delayed motor milestones but normal cognitive development   \n\u2022 Muscle weakness of limb-girdle distribution, myopathic face, variable degree of ptosis, and relative calf muscle hypertrophy   \n\u2022 Development of dilated cardiomyopathy between ages fve and 16 years   \n\u2022 Major heart rhythm disturbances leading to sudden death before age 20 years \nm creatine kinase (CK) is marginally to moderately increase \nElectrophysiologic \n\u2022 Electrocardiography. Lef axis deviation (lef anterior fascicular block) can be seen as early as age four years (Figure 1). With the onset of dilated cardiomyopathy, rhythm disturbances can include polymorphic premature ventricular complexes, bigeminism and trigeminism, couplets, triplets, atrioventricular heart block, atrioventricular nodal reentrant tachycardia, premature atrial complexes, premature ventricular complexes, and ventricular tachycardia.   \n\u2022 Electromyography shows myopathic features (low-amplitude polyphasic potentials of short duration).   \n\u2022 Nerve conduction studies are normal. \n",
      "token_count": 452,
      "sentence_count": 21
    },
    {
      "id": "brugada_txt_32",
      "contents": " Manifestation of Brugada syndrome afer pacemaker implantation in a patient with sick sinus syndrome. J Cardiovasc Electrophysiol. 2004;15:1328\u201330. PubMed PMID: 15574187.   \nNamiki T, Ogura T, Kuwabara Y, et al. Five-year mortality and clinical characteristics of adult subjects with right bundle branch block and ST elevation. Circulation. 1995;93:334.   \nNunn L, Bhar-Amato J, Lambiase P. Brugada syndrome: controversies in risk stratifcation and management. Indian Pacing Electrophysiol J. 2010;10:400\u20139. PubMed PMID: 20930958.   \nOe H, Takagi M, Tanaka A, Namba M, Nishibori Y, Nishida Y, Kawarabayashi T, Yoshiyama M, Nishimoto M, Tanaka K, Yoshikawa J. Prevalence and clinical course of the juveniles with Brugada-type ECG in Japanese population. Pacing Clin Electrophysiol. 2005;28:549\u201354. PubMed PMID: 15955188.   \nOhno S, Zankov DP, Ding WG, Itoh H, Makiyama T, Doi T, Shizuta S, Hattori T, Miyamoto A, Naiki N, Hancox JC, Matsuura H, Horie M. KCNE5 (KCNE1L) variants are novel modulators of Brugada syndrome and idiopathic ventricular fbrillation. Circ Arrhythm Electrophysiol. 2011;4:352\u201361. PubMed PMID: 21493962.   \nOlson TM, Alekseev AE, Moreau C, Liu XK, Zingman LV, Miki T, Seino S, Asirvatham SJ, Jahangir A, Terzic A. KATP channel mutation confers risk for vein of Marshall adrenergic atrial fbrillation. Nat Clin Pract Cardiovasc Med. 2007;4:110\u20136. PubMed PMID: 17245405.   \n",
      "token_count": 458,
      "sentence_count": 28
    },
    {
      "id": "cvt_txt_3",
      "contents": "\u2022 History of exercise- or emotion-related palpitations and dizziness in some individuals   \n\u2022 Sudden unexpected cardiac death triggered by acute emotional stress or exercise   \n\u2022 Family history of juvenile sudden cardiac death triggered by exercise or acute emotion   \n\u2022 Exercise-induced bidirectional or polymorphic ventricular arrhythmias \u26ac EKG during a graded exercise (exercise stress test) \\* allows ventricular arrhythmias to be reproducibly elicited in the majority of afected individuals. Typically, the onset of ventricular arrhythmias is 90-120 beats per minute. \u26ac With increase in workload, the complexity of arrhythmias progressively increases from isolated premature beats to bigeminy and runs of non-sustained ventricular tachycardia (VT). If the afecte d individual continues exercising, the duration of the runs of VT progressively increases and VT may become sustained. \u26ac An alternating $180^{\\circ}$ -QRS axis on a beat-to-beat basis, so-called bidirectional VT, is ofen the distinguishing presentation of CPVT arrhythmias [Priori et al 2021]. \u26ac Notably, some individuals with CPVT may also present with irregular polymorphic VT without a \"stable\" QRS vector alternans [Swan et al 1999, Priori et al 2002]. \u26ac Exercise-induced supraventricular arrhythmias (supraventricular tachycardia and atrial fbrillatio n) are common [Leenhardt et al 1995, Fisher et al 1999]. \n\u2022 Ventricular fbrillation occurring in the setting of acute stress \\* Note: Te resting EKG of individuals with CPVT is usually normal. Some authors have reported a lower-thannormal resting heart rate [Postma et al 2005] and others have observed a high incidence of prominent U waves, particularly in the precordial leads [Leenhardt et al 1995, Aizawa et al 2006]. Overall, these features are inconsistent and not sufciently specifc to allow diagnosis. Terefore, in many instances the origin of the syncope may be erroneously attributed to a neurologic disorder. Te exercise stress test is the single most important diagnostic test.",
      "token_count": 485,
      "sentence_count": 15
    },
    {
      "id": "brugada_txt_7",
      "contents": " Electrical storms (also known as arrhythmic storms) \u2013 multiple episodes of ventricular \narrhythmias that occur over a short period of time \u2013 are malignant but rare phenomena in Brugada syndrome.   \nIncessant ventricular tachycardia (VT) is defned as hemodynamically stable VT continuing for hours. \nBrugada syndrome can occur in conjunction with conduction disease. Te presence of frst-degree AV block, intraventricular conduction delay, right bundle branch block, and sick sinus syndrome in Brugada syndrome is not unusual [Smits et al 2005]. \nClinical presentations of Brugada syndrome may also include sudden infant death syndrome (SIDS; death of a child during the frst year of life without an identifable cause) [Priori et al 2000, Antzelevitch 2001, Skinner et al 2005, Van Norstrand et al 2007] and sudden unexpected nocturnal death syndrome (SUNDS) [Vatta et al 2002], a syndrome seen in Southeast Asia in which young people die from cardiac arrest with no identifable cause.  Te same pathogenic variant in SCN5A was identifed in individuals with Brugada syndrome and SUNDS, thus supporting the hypothesis that they are the same disease [Hong et al 2004a]. \nPrecipitating factors for the Brugada EKG pattern and the syndrome of sudden cardiac death include fever, cocaine use, electrolyte disturbances, and use of class I antiarrhythmic medications and a number of other noncardiac medications [Francis & Antzelevitch 2005]. Most importantly, in some (usually young) persons, the presence of the induced EKG pattern has been associated with sudden cardiac death. Te pathophysiologic mechanisms behind this association remain largely unknown. \nPredicting risk of malignant arrhythmias. Several parameters have been investigated to improve stratifcatio n of the risk of developing malignant arrhythmias (see Figure 3). \n\u2022 Inducibility during electrophysiologic study (EPS) is the only parameter currently used for clinical decision making. During such a study the heart is electrically stimulated using intracardiac catheters.",
      "token_count": 464,
      "sentence_count": 14
    },
    {
      "id": "dcm-lmna_txt_5",
      "contents": " In another retrospective study of 122 individuals with LMNA pathogenic variants, of those who had preserved lef ventricular function and no heart failure at the time of presentation, new-onset lef ventricular dysfunction or heart failure was observed in ${\\sim}24\\%$ and $7\\%$ of individuals, respectively, afer seven years [Kumar et al 2016]. \n\u2022 Conduction system involvement usually starts with disease of the sinus node and/or atrioventricular node that can manifest as sinus bradycardia, sinus node arrest with junctional rhythms, or heart block (commonly frst-degree heart block that progresses to second- and third-degree block). Te following are also common: \n\u26ac Symptomatic bradyarrhythmias requiring cardiac pacemakers   \n\u26ac Supraventricular arrhythmias including atrial futter, atrial fbrillation, supraventricular tachycardia, and the sick sinus syndrome (i.e., tachycardia-bradycardia syndrome)   \n\u26ac Ventricular arrhythmias including frequent premature ventricular contractions, ventricular tachycardia, and ventricular fbrillation \n\u2022 Sudden cardiac death may occur with progressive disease. Although more malignant, life-threatening arrhythmias may occur with longstanding and usually previously symptomatic DCM, sudden cardiac \ndeath can also be the presenting manifestation of LMNA-related DCM, with minimal or no  lef ventricular dysfunction [Meune et al 2006].   \n\u2022 Variable DCM. Only mild-to-moderate lef ventricular dilatation despite progressive disease has been noted by some investigators. Terefore, LMNA-related DCM may be an appropriate diagnosis in those with an LMNA pathogenic variant who have clinical conduction system disease and/or arrhythmia prior to the lef ventricular enlargement or with minimal or no systolic dysfunction.   \n\u2022 Skeletal muscle disorder. Occasionally, individuals with LMNA-related cardiomyopathy also manifest signs or symptoms of skeletal myopathy, which may be associated with elevated serum creatine kinase concentration. \nLarge prospective longitudinal studies to defne the range of natural history of individuals with LMNA pathogenic variants have not yet been published. \n",
      "token_count": 492,
      "sentence_count": 16
    },
    {
      "id": "arvd_txt_5",
      "contents": "100\\,\\mathrm{mL}/\\mathrm{m}^{2}$ to $<\\!110\\;\\mathrm{mL}/\\mathrm{m}^{2}$ (male) or $\\geq\\!90\\;\\mathrm{mL}/\\mathrm{m}^{2}$ to ${<}100\\;\\mathrm{mL}/\\mathrm{m}^{2}$ (female) \u25aa RV ejection fraction ${>}40\\%$ to ${\\le}45\\%$ \nEndomyocardial Biopsy or Autopsy Findings \nMajor. Residual myocytes ${<}60\\%$ by morphometric analysis (or ${<}50\\%$ if estimated), with fbrous replacement of the RV free wall myocardium in at least one sample, with or without fatty replacement of tissue \nMinor. Residual myocytes $60\\%-75\\%$ by morphometric analysis (or $50\\%{-}65\\%$ if estimated), with fbrou s replacement of the RV free wall myocardium in at least one sample, with or without fatty replacement of tissue \nEKG Findings \nRepolarization abnormalities \n\u2022 Major. Inverted T waves in right precordial leads (V1, V2, and V3) or beyond in individuals age ${>}14$ years (in the absence of complete right bundle branch block $\\mathrm{QRS}\\,{\\geq}120~\\mathrm{ms})$ \n\u2022 Minor \u26ac Inverted T waves in leads V1 and V2 in individuals age ${>}14$ years (in absence of complete right bundle branch block) or in V4, V5, or V6 \u26ac Inverted T waves in leads V1, V2, V3, and V4 in individuals age ${>}14$ years in the presence of complete right bundle branch block \nDepolarization/conduction abnormalities \n\u2022 Major. Epsilon waves (reproducible low-amplitude signals between end of QRS complex to onset of the T wave) in the right precordial leads (V1 to V3)   \n",
      "token_count": 468,
      "sentence_count": 12
    },
    {
      "id": "brugada_txt_14",
      "contents": "\u2022 EKG changes have low sensitivity in establishing the diagnosis [Corcia 2022]; \u2022 Identifcation of individuals at risk allows preventive measures such as fever control and avoidance of medications that can induce ventricular arrhythmias; Cardiac surveillance can be limited to family members who have the familial Brugada syndrome-related pathogenic variant [Benito et al 2009, Esc\u00e1rcega et al 2009, Nunn et al 2010]. \nIndividuals with a known pathogenic variant should undergo EKG monitoring every one to two years beginning at birth (see Surveillance). \nIf the pathogenic variant has not been identifed in the family, relatives should undergo EKG monitoring every one to two years beginning at birth (see Surveillance). If a type I EKG is identifed, further investigation is warranted. \nSee Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes. \nPregnancy Management \nHormonal changes during pregnancy can precipitate arrhythmic events in women with Brugada syndrome. Recurrent ventricular tachyarrhythmia can be inhibited, and the electrocardiographic pattern can normalize following IV infusion of low-dose isoproterenol followed by oral quinidine [Sharif-Kazemi et al 2011]. \nQuinidine is not known to be teratogenic to the developing fetus and is a preferred drug to treat arrhythmia in pregnancy. See MotherToBaby for more information about medication use during pregnancy. \nTherapies Under Investigation \nSearch ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: Tere may not be clinical trials for this disorder. \nGenetic Counseling \nGenetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions.  Te following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. \u2014ED. \nMode of Inheritance \n",
      "token_count": 470,
      "sentence_count": 18
    },
    {
      "id": "dcm-lmna_txt_0",
      "contents": "LMNA-Related Dilated Cardiomyopathy \nRay E Hershberger, ${\\mathsf{M D}}^{1}$ and Elizabeth Jordan, MMSc, CGC2 Created: June 12, 2008; Updated: March 17, 2022. \nSummary \nClinical characteristics \nLMNA-related dilated cardiomyopathy (DCM) is characterized by lef ventricular enlargement and/or reduced systolic function preceded (sometimes by many years) by or accompanied by conduction system disease and/or arrhythmias. LMNA-related DCM usually presents in early to mid-adulthood with symptomatic conduction system disease or arrhythmias, or with symptomatic DCM including heart failure or embolus from a  lef ventricular mural thrombus. Sudden cardiac death can occur, and in some instances is the presenting manifestation; sudden cardiac death may occur with minimal or no systolic dysfunction. \nDiagnosis/testing \nTe diagnosis of LMNA-related DCM is established in a proband with suggestive fndings and a heterozygous pathogenic variant in LMNA identifed by molecular genetic testing. \nManagement \nTreatment of manifestations: Chronic atrial fbrillation is treated initially with attempts to restore normal sinus rhythm, anticoagulation, and rate control. Symptomatic supraventricular arrhythmias are usually treated with pharmacologic therapy or ablation; symptomatic bradyarrhythmias or signifcant heart block is treated with an electronic pacemaker. Symptomatic ventricular arrhythmias, ventricular tachycardia, ventricular fbrillation, and resuscitated sudden cardiac death are treated with an implantable cardioverter defbrillator (ICD) and drug therapy as needed. Because risk for sudden cardiac death in LMNA-related DCM accompanies heart block and bradyarrhythmias, ICD use (rather than just pacemaker use) has been recommended for all indications. Treatment of symptomatic DCM, including heart failure, is pharmacologic with ACE inhibitors, beta blockers, and other conventional approaches. Progressive deterioration in lef ventricular function is treated with an ICD.",
      "token_count": 491,
      "sentence_count": 14
    },
    {
      "id": "arvd_txt_6",
      "contents": "\u2022 Minor \u26ac Late potential by signal-averaged EKG in at least one of three parameters in the absence of a QRS duration of ${\\geq}110~\\mathrm{ms}$ on standard EKG \u26ac Filtered QRS duration $(\\mathrm{fQRS})\\,{\\geq}114\\,\\mathrm{ms}$ $^\\circ$ Duration of terminal QRS ${<}40\\,\\mathrm{uV}$ (low-amplitude signal duration) ${\\geq}38$ ms \u26ac Root-mean-square voltage of terminal $40\\;\\mathrm{ms}\\leq20\\;\\mathrm{uV}$ \n\u26ac Terminal activation duration of $\\mathrm{QRS}>55~\\mathrm{ms}$ measured from the nadir of the S wave to the end of the QRS, including $\\mathrm{R}^{\\prime}$ , in V1, V2, or V3 in the absence of complete right bundle branch block \nArrhythmias \n\u2022 Major. Nonsustained or sustained ventricular tachycardia of lef bundle branch morphology with superior axis (negative or indeterminate QRS in leads II, III, and aVF and positive in lead aVL)   \n\u2022 Minor \u26ac Nonsustained or sustained ventricular tachycardia of RV outfow confguration, lef bundle branch block morphology with inferior axis (positive QRS in leads II, III, and aVF and negative in lead aVL) or of unknown axis \u26ac ${>}500$ ventricular extrasystoles per 24 hours (Holter) \nFamily History and Molecular Genetic Testing \nMajor \n\u2022 ARVC confrmed in a frst-degree relative who meets 2010 Task Force Criteria [Marcus et al 2010] \u2022 ARVC confrmed pathologically at autopsy or surgery in a frst-degree relative \u2022 Identifcation of a pathogenic variant categorized as associated or probably associated with ARVC in the proband \nMinor \n",
      "token_count": 433,
      "sentence_count": 6
    },
    {
      "id": "thompson_thompson_genetics_8th_edition_medicoscompanion_com_txt_766",
      "contents": " The couple wants to know the recurrence risk for this condition in their children and the genetic testing and prenatal diagnosis options that might be available to them. She is also concerned about potential risks to her own health in carrying a pregnancy. The patient was diagnosed with the LQT syndrome in her early 20s when she was evaluated after the sudden death of her 15-year-old brother. Overall, she is a healthy individual with normal hearing, no dysmorphic features, and an otherwise negative review of systems. She has never had any fainting episodes. Subsequently, electrocardiographic findings confirmed the diagnosis of the syndrome in A.B., and a paternal aunt but not in her father, who had a normal QTc interval. Molecular testing revealed a missense mutation in KCNH2, one that had been previously seen in other families with Romano-Ward syndrome, type LQT2. A.B. was initially prescribed $\\upbeta$ -blockade medication, which she is continuing, but her cardiologists decided that the less than total efficacy of $\\upbeta$ -blockers in LQT2 and the previous lethal event in her brother justified the use of an implantable cardioverter-defibrillators in A.B. and her affected relatives. A.B. is the first person in her family to pursue genetic counseling for the LQT syndrome. \nBACKGROUND \nDisease Etiology and Incidence \nThe LQT syndromes are a heterogeneous, panethnic group of disorders referred to as channelopathies because they are caused by defects in cardiac ion channels. The overall prevalence of LQT disorders is approximately 1 in 5000 to 7000 individuals. \nThe genetics underlying LQT syndromes is complex. First, there is locus heterogeneity. Mutations in at least five known cardiac ion channel genes (KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2) are responsible for most cases of LQT; mutations in additional genes are known, but much rarer. Second, different mutant alleles in the same locus can result in two distinct LQT syndromes with two different inheritance patterns, the Romano-Ward syndrome and the autosomal recessive Jervell and Lange-Nielsen syndrome (MIM 220400). \nPathogenesis \n",
      "token_count": 485,
      "sentence_count": 19
    },
    {
      "id": "A_Guide_To_Marfan_Syndrome_and_Related_Disorders_txt_3",
      "contents": " Other people have a spontaneous mutation, meaning that they are the first person in their family to have Marfan syndrome. People with Marfan syndrome have a $50\\%$ chance of passing the mutation on each time they have a child. \nPeople are born with Marfan syndrome but may not notice any features until later in life. Marfan syndrome features can appear at any age, including in infants and young children. They often get worse as people age. \n3. WHAT IS THE PROGNOSIS FOR PEOPLE WITH MARFAN SYNDROME? \nThere is no cure for Marfan syndrome, but with early diagnosis, proper treatment and careful management of the disorder, it is possible for people to live a normal life span. The outlook today for people with Marfan syndrome is far brighter than it was a few decades ago. In the days before open-heart surgery, the average life expectancy was reduced by a third. Now, early diagnosis and careful management have greatly improved the prognosis and increased life expectancy. Medical and surgical treatments continue to improve and offer hope to even the most severely affected infants, children and adults. In addition, proper management can relieve or prevent many of the complications that interfere with daily activities. \n1.HOW IS MARFAN SYNDROME DIAGNOSED? \nAlthough scientists have determined that Marfan syndrome is caused by a variation in the fibrillin-1 gene on chromosome 15, there is no simple test that can conclusively diagnose Marfan syndrome. Therefore, diagnosis is made primarily through a clinical evaluation. Genetic testing may be helpful in some situations (see page 22). \nBecause most features of Marfan syndrome progress with age, the diagnosis is often more obvious in teens or adults. But children, even newborns, can and should be examined. For these reasons, the diagnostic evaluation should be performed by physicians experienced with the condition. The evaluation should include: \nA detailed medical and family history.   \nA complete physical examination.   \nA thorough eye examination by an eye specialist (ophthalmologist) using a slit lamp to look for lens dislocation after fully dilating the pupil.   \nAn electrocardiogram (EKG) and an echocardiogram to look for involvement of the cardiovascular system that may be not evident from the physical examination. \n",
      "token_count": 453,
      "sentence_count": 24
    },
    {
      "id": "26431_txt_211",
      "contents": " Approximately 40 percent of healthy adolescents would be misclassified as having POTS using the adult heart rate increment of 30 bpm (Singer et al., 2012). At all ages, the diagnosis of POTS is based on more than just the heart rate and also requires the individual to have chronic orthostatic symptoms. Heart rate elevation alone is insufficient for a diagnosis of POTS in individuals who are dehydrated or are being treated with vasodilating medications. Conversely, at the time of orthostatic testing, concurrent consumption of substances that increase plasma volume, such as salt tablets, or agents used to treat orthostatic intolerance (e.g., serotonin reuptake inhibitors, oral contraceptives, stimulant medications, beta adrenergic antagonists, or other medications) can obscure the diagnosis of POTS. \nInappropriate Sinus Tachycardia \nAs the name suggests, this condition is diagnosed when the patient is in sinus rhythm, but has a heart rate higher than 100 bpm at rest. Symptoms of inappropriate sinus tachycardia are similar to those in POTS (Sheldon et al., 2015). \nNeurally Mediated Hypotension \nNMH is a reflex form of hypotension, and while its physiology is synonymous with vasovagal syncope or neurocardiogenic syncope (BouHolaigah et al., 1995; Grubb, 2005; Rowe et al., 1995), NMH is a more accurate description of the phenotype. Many with NMH experience the same characteristically abrupt drop in blood pressure during tilt testing as those with vasovagal syncope, and they can experience chronic daily orthostatic symptoms without having completely lost consciousness. In both children and adults, NMH occurs after the 3-minute cutoff for orthostatic hypotension and is characterized by at least a $25~\\mathrm{mm\\;Hg}$ reduction in systolic blood pressure. At the time of presyncope or hypotension, affected individuals can develop a relative slowing of the heart rate that can progress to junctional bradycardia or even asystole.",
      "token_count": 461,
      "sentence_count": 15
    },
    {
      "id": "barth_txt_9",
      "contents": " Spencer et al [2006] observed that with standard cardiac medications for dilated cardiomyopathy more than 16/30 afected males had normal ejection fraction and lef ventricular diastolic volume. However, some responded to therapy initially but deteriorated afer a period of stability, requiring cardiac transplantation [Adwani et al 1997, Mangat et al 2007]. \nArrhythmia. Te risk for arrhythmia (including supraventricular and ventricular tachycardia) and sudden death is increased. While arrhythmia has been most ofen reported in adolescents and young adults, it can occur in children of all ages. EKG abnormalities can include repolarization abnormalities and prolonged QTc intervals. \nAll 20 afected males with EKGs in the French cohort had a normal sinus rhythm. Repolarization abnormalities (including ST fattening and T-wave inversion) were seen in 17. Five had QTc values within the normal range (QTc ${<}420\\;\\mathrm{ms}_{}$ ), and fve had QTc greater than $460\\:\\mathrm{ms}$ . Te median QTc was $440\\:\\mathrm{ms}$ (range: $360{-}530~\\mathrm{ms})$ ). In the study by Kang et al [2016], nine of 21 afected individuals had prolonged QTc of greater than $460~\\mathrm{ms}$ and three had borderline QTc prolongation between 450 and $460~\\mathrm{ms}$ . \nIn fve instances of ventricular arrhythmia leading to cardiac arrest or placement of an internal defbrillato r [Spencer et al 2005]: \n\u2022 All fve individuals had normal QTc intervals;   \n\u2022 All fve had a history of recurrent vasovagal symptoms including postural dizziness, nausea, and pallor suggestive of autonomic instability;   \n\u2022 Four had only mild LV dilatation and low normal to mildly depressed LV function; only one had poor but stable LV function prior to cardiac arrest;   \n\u2022 Tree showed inducible ventricular arrhythmias on electrophysiologic testing;   \n",
      "token_count": 479,
      "sentence_count": 15
    },
    {
      "id": "jln_txt_15",
      "contents": "Therapies Under Investigation \nSearch ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: Tere may not be clinical trials for this disorder. \nOther \nFamily members of individuals with JLNS should be trained in cardiopulmonary resuscitation (CPR) as up to $95\\%$ of individuals with JLNS have a cardiac event before adulthood [Schwartz et al 2006]. \nAfected individuals should wear an ID bracelet explaining their diagnosis. \nIt is appropriate to notify local emergency medical services (EMS) of high-risk persons, including those with JLNS [Hazinski et al 2004]. \nGenetic Counseling \nGenetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions.  Te following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. \u2014ED. \nMode of Inheritance \nJervell and Lange-Nielsen syndrome (JLNS) is inherited in an autosomal recessive manner. \nRisk to Family Members \nParents of a proband \n\u2022 Parents of a child with JLNS are usually obligate heterozygotes (i.e., carriers of one KCNQ1 or KCNE1 pathogenic variant). In rare cases, only one parent is heterozygous and the other pathogenic variant in the proband is de novo [Schwartz et al 2000].   \n\u2022 Parents may or may not have the long QT syndrome (LQTS) phenotype. Studies have documented autosomal dominant inheritance of moderately prolonged QTc intervals in some, but not all, families in which one or more sibs have JLNS [Splawski et al 1997].   \n\u2022 Recommendations for evaluation of the parents of a child with JLNS include: \u26ac Molecular genetic testing if the pathogenic variants have been identifed; \u26ac Comprehensive electrocardiographic testing for evidence of QTc prolongation by a physician familiar with LQTS. \nSibs of a proband \n",
      "token_count": 482,
      "sentence_count": 21
    },
    {
      "id": "thompson_thompson_genetics_8th_edition_medicoscompanion_com_txt_767",
      "contents": "LQT syndrome is caused by repolarization defects in cardiac cells. Repolarization is a controlled process that requires a balance between inward currents of sodium and calcium and outward currents of potassium. Imbalances cause the action potential of cells to increase or decrease in duration, causing elongation or shortening, respectively, of the QT interval on electrocardiography. Most cases of LQT syndrome are caused by loss-of-function mutations in genes that encode subunits or regulatory proteins for potassium channels (genes whose names begin with KCN). These mutations decrease the outward, repolarization current, thereby prolonging the action potential of the cell and lowering the threshold for another depolarization. In other LQT syndrome patients, gain-of-function mutations in a sodium channel gene, SCN5A, lead to an increased influx of sodium, resulting in similar shifting of action potential and repolarization effects. \nPhenotype and Natural History \nThe LQT syndromes are characterized by elongated QT interval and T-wave abnormalities on electrocardiography (Fig. C-28), including tachyarrhythmia and torsades de pointes, a ventricular tachycardia characterized by a change in amplitude and twisting of the QRS complex. Torsades de pointes is associated with a prolonged QT interval and typically stops spontaneously but may persist and worsen to ventricular fibrillation. \n\nIn the most common LQT syndrome, Romano-Ward, syncope due to cardiac arrhythmia is the most frequent symptom; if undiagnosed or left untreated, it recurs and can be fatal in $10\\%$ to $\\bar{1}5\\%$ of cases. However, between $30\\%$ and $50\\%$ of individuals with the syndrome never show syncopal symptoms. Cardiac episodes are most frequent from the preteen years through the 20s, with the risk decreasing over time. Episodes may occur at any age when triggered by QTprolonging medications (see list at http://www.qtdrugs.org). Nonpharmacological triggers for cardiac events in the Romano-Ward syndrome differ on the basis of the gene responsible. LQT1 triggers are typically adrenergic stimuli, including exercise and sudden emotion.",
      "token_count": 492,
      "sentence_count": 16
    },
    {
      "id": "acpp_txt_15",
      "contents": " \u2022 If the pathogenic variant in the family is not known, detailed neurologic and cardiologic evaluation, 12- lead EKG, and 24-hour Holter monitoring can be used to clarify the disease status of at-risk relatives. \nSee Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes. \nPregnancy Management \nTe rarity of ATS and the paucity of reports pertaining to pregnancy in women with ATS make an evidencebased approach to pregnancy management difcult to formulate. One case study reported an uneventful pregnancy, with increased episodes of weakness but reduced ventricular ectopy compared to the pre-pregnancy period [Subbiah et al 2008]. However, as data are limited, a multidisciplinary approach to individual care and anticipation of increased risk (as can be seen in those with long QT syndrome) seems reasonable. \nTherapies Under Investigation \nSearch ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: Tere may not be clinical trials for this disorder. \nGenetic Counseling \nGenetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions.  Te following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. \u2014ED. \nMode of Inheritance \nAndersen-Tawil syndrome (ATS) is inherited in an autosomal dominant manner. \nRisk to Family Members \nParents of a proband \n\u2022 At least $50\\%$ of individuals diagnosed with ATS have an afected parent. \u2022 A proband with ATS may have the disorder as the result of a de novo KCNJ2 pathogenic variant.  Te proportion of cases caused by a de novo pathogenic variant in KCNJ2 may be as high as $50\\%$ .",
      "token_count": 433,
      "sentence_count": 20
    },
    {
      "id": "acpp_txt_2",
      "contents": "\u2022 Periodic paralysis Symptomatic cardiac arrhythmias or electrocardiographic evidence of enlarged U-waves, ventricular ectopy, or a prolonged QTc or QUc interval Characteristic facies, dental anomalies, small hands and feet, AND at least two of the following: \u26ac Low-set ears \u26ac Widely spaced eyes \u26ac Small mandible \u26ac Fifh-digit clinodactyly \u26ac Syndactyly of toes 2 and 3 \nB. One of the above three criteria AND at least one other family member who meets two of the three criteria [Statland et al 2018] \nSupportive Findings \nIndividuals with either episodic weakness or cardiac symptoms require careful evaluation by a neurologist and/or cardiologist as well as measurement of serum potassium concentration (baseline and during attacks of faccid paralysis), a 12-lead EKG, a 24-hour Holter monitor, and possibly the long exercise protocol. \n\u2022 Serum potassium concentration during episodes of weakness may be elevated, normal, or, most commonly, reduced $^{(<3.5\\;\\mathrm{mmol}/\\mathrm{U})}$ [Sansone & Tawil 2007, Statland et al 2018]. \n\u2022 Routine nerve conduction electrophysiology is normal between episodes. A more sensitive electrophysiologic study, the long exercise protocol, may reveal an immediate post-exercise increment followed by an abnormal decrement in the compound motor action potential amplitude $(\\sqrt{\\frac{}{}40\\%})$ [Katz et al 1999] or area $(>\\!50\\%)$ 20-40 minutes post exercise [Kuntzer et al 2000, Fournier et al 2004]. In a study of 11 individuals with ATS, $82\\%$ met long-exercise amplitude decrement criteria for abnormal testing [Tan et al 2011]. \u2022 Electrocardiogram may reveal characteristic abnormalities including prominent U waves, prolonged Q-U intervals, premature ventricular contractions, polymorphic ventricular tachycardia, and bidirectional ventricular tachycardia [Zhang et al 2005, Delannoy et al 2013, Koppikar et al 2015, Statland et al 2018].",
      "token_count": 479,
      "sentence_count": 11
    },
    {
      "id": "edmd_txt_2",
      "contents": "\u2022 Slowly progressive wasting and weakness typically of the humero-peroneal/scapulo-peroneal muscles in the early stages   \n\u2022 Cardiac disease with conduction defects and arrhythmias \u26ac Atrial fbrillation, futter and standstill, supraventricular and ventricular arrhythmias, and atrioventricular and bundle-branch blocks may be identifed on resting electrocardiography (EKG) or by 24-hour ambulatory EKG. \u26ac Dilated or hypertrophic cardiomyopathy may be detected by the performance of echocardiographic evaluation. \nAge of onset. Onset usually occurs between age fve and ten years, rarely before age fve years. \nFamily history. May be positive (autosomal dominant, X-linked, or, rarely, autosomal recessive). However, simplex cases as a result of de novo genetic events are not rare. \nNote: Diagnosis guidelines have been published [Emery 1997, Bonne et al 2002b, Madej-Pilarczyk 2018]. \nEstablishing the Diagnosis \nTe diagnosis of EDMD is established in a proband with a clearly relevant clinical picture including limb muscle wasting and/or weakness and elbow or neck/spine joint contractures (cardiac disease may be missing in the frs t decades of life) and a hemizygous pathogenic (or likely pathogenic) variant in EMD or FHL1, a heterozygous pathogenic (or likely pathogenic) variant in LMNA, or (more rarely) biallelic pathogenic (or likely pathogenic) variants in LMNA identifed by molecular genetic testing (see Table 1). \nNote: (1) Per ACMG/AMP variant interpretation guidelines, the terms \"pathogenic variants\" and \"likely pathogenic variants\" are synonymous in a clinical setting, meaning that both are considered diagnostic and both can be used for clinical decision making [Richards et al 2015]. Reference to \"pathogenic variants\" in this section is understood to include any likely pathogenic variants. (2) Te identifcation of variant(s) of uncertain signifcance cannot be used to confrm or rule out the diagnosis. \n",
      "token_count": 464,
      "sentence_count": 14
    },
    {
      "id": "cvt_txt_11",
      "contents": " Recommended Surveillance for Individuals with Catecholaminergic Polymorphic Ventricular Tachycardia \nAgents/Circumstances to Avoid \nCompetitive sports and other strenuous exercise are always contraindicated for individuals with CPVT. All individuals showing exercise-induced arrhythmias should avoid physical activity, except for light training for those individuals showing good suppression of arrhythmias on exercise stress testing while on therapy. It is important to note that efcacy needs to be periodically retested [Heidb\u00fcchel et al 2006]. Te risk for arrhythmias during sports in individuals who have pathogenic variants in genes associated with CPVT but no clinical phenotype (no exercise-induced arrhythmias) is not known; thus, it may be safest for these individuals to refrain from intense physical activity. \nDigitalis favors the onset of cardiac arrhythmias as a result of delayed aferdepolarization and triggered activity;   \ntherefore, digitalis should be avoided in all individuals with CPVT. \nEvaluation of Relatives at Risk \nBecause treatment and surveillance are available to reduce morbidity and mortality, frst-degree relatives should be ofered clinical evaluation and molecular genetic testing if the family-specifc pathogenic variant(s) are known. Te availability of efective preventive therapies can reduce the number of fatal arrhythmic events if individuals with pathogenic variants are diagnosed early. \nIf the family-specifc pathogenic variant(s) are not known, all frst-degree relatives of an afected individual should be evaluated with resting EKG, Holter monitoring, echocardiography, and \u2013 most importantly \u2013 exercise stress testing. \nSee Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes. \nPregnancy Management \nBeta blockers (preferentially nadolol or propranolol) should be administered throughout pregnancy in afecte d women. \nSee MotherToBaby for information on medication use during pregnancy. \nTherapies Under Investigation \nSearch ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. \nGenetic Counseling \nGenetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions.",
      "token_count": 490,
      "sentence_count": 21
    },
    {
      "id": "brugada_txt_29",
      "contents": "Ikeda T, Takami M, Sugi K, Mizusawa Y, Sakurada H, Yoshino H. Noninvasive risk stratifcation of subjects with a Brugada-type electrocardiogram and no history of cardiac arrest. Ann Noninvasive Electrocardiol. 2005;10:396\u2013403. PubMed PMID: 16255748.   \nImaki R, Niwano S, Fukaya H, Sasaki S, Yuge M, Hirasawa S, Sato D, Sasaki T, Moriguchi M, Izumi T. Predictive impact of the inducibility of ventricular fbrillation in patients with Brugada-type ECG. Int Heart J. 2006;47:229\u201336. PubMed PMID: 16607050.   \nIto H, Yano K, Chen R, He Q, Curb JD. Te prevalence and prognosis of a Brugada-type electrocardiogram in a population of middle-aged Japanese-American men with follow-up of three decades. Am J Med Sci. 2006;331:25\u20139. PubMed PMID: 16415660.   \nKapplinger JD, Tester DJ, Alders M, Benito B, Berthet M, Brugada J, Brugada P, Fressart V, Guerchicof A, Harris-Kerr C, Kamakura S, Kyndt F, Koopmann TT, Miyamoto Y, Pfeifer R, Pollevick GD, Probst V, Zumhagen S, Vatta M, Towbin JA, Shimizu W, Schulze-Bahr E, Antzelevitch C, Salisbury BA, Guicheney P, Wilde AA, Brugada R, Schott JJ, Ackerman MJ. An international compendium of mutations in the SCN5Aencoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm. 2010;7:33\u201346. PubMed PMID: 20129283.   \nKaraca M, Dinckal MH. Monomorphic and propafenone-induced polymorphic ventricular tachycardia in Brugada syndrome: a case report. Acta Cardiol. 2006;61:481\u20134.",
      "token_count": 485,
      "sentence_count": 24
    },
    {
      "id": "brugada_txt_20",
      "contents": "Belhassen B, Glick A, Viskin S. Efcacy of quinidine in high-risk patients with Brugada syndrome. Circulation. 2004;110:1731\u20137. PubMed PMID: 15381640.   \nBenito B, Brugada J. Recurrent syncope: an unusual presentation of Brugada syndrome. Nat Clin Pract Cardiovasc Med. 2006;3:573\u20137. PubMed PMID: 16990843.   \nBenito B, Brugada J, Brugada R, Brugada P. Brugada syndrome. Rev Esp Cardiol. 2009;62:1297\u2013315. PubMed PMID: 19889341.   \nBenson DW, Wang DW, Dyment M, Knilans TK, Fish FA, Strieper MJ, Rhodes TH, George AL Jr. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J Clin Invest. 2003;112:1019\u201328. PubMed PMID: 14523039.   \nBerne P, Brugada J. Brugada syndrome 2012. Circ J. 2012;76:1563\u201371. PubMed PMID: 22789973.   \nBrugada J, Brugada P, Brugada R. Te syndrome of right bundle branch block ST segment elevation in V1 to V3 and sudden death--the Brugada syndrome. Europace. 1999a;1:156\u201366. PubMed PMID: 11225790.   \nBrugada J, Campuzano O, Arbelo E, Sarquella-Brugada G, Brugada R. Present status of Brugada syndrome: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72:1046\u201359. PubMed PMID: 30139433.   \nBrugada P, Brugada R, Brugada J, Geelen P. Use of the prophylactic implantable cardioverter defbrillator for patients with normal hearts. Am J Cardiol. 1999b;83:98D\u2013100D. PubMed PMID: 10073791.   \n",
      "token_count": 471,
      "sentence_count": 38
    },
    {
      "id": "brugada_txt_38",
      "contents": " Eur Heart J. 2011;32:1077\u201388. PubMed PMID: 21383000.   \nTohyou Y, Nakazawa K, Ozawa A, Tanaka O, Watanuki M, Takagi A, Akagi T, Masui Y, Matumoto N, Miyake F, Murayama M. A survey in the incidence of right bundle branch block with ST segment elevation among normal population. Jpn J Electrocardiol. 1995;15:223\u20136.   \nVan Norstrand DW, Valdivia CR, Tester DJ, Ueda K, London B, Makielski JC, Ackerman MJ. Molecular and functional characterization of novel glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) mutations in sudden infant death syndrome. Circulation. 2007;116:2253\u20139. PubMed PMID: 17967976.   \nVatta M, Dumaine R, Varghese G, Richard TA, Shimizu W, Aihara N, Nademanee K, Brugada R, Brugada J, Veerakul G, Li H, Bowles NE, Brugada P, Antzelevitch C, Towbin JA. Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet. 2002;11:337\u201345. PubMed PMID: 11823453.   \nViswanathan PC, Benson DW, Balser JR. A common SCN5A polymorphism modulates the biophysical efects of an SCN5A mutation. J Clin Invest. 2003;111:341\u20136. PubMed PMID: 12569159.   \nWang DW, Viswanathan PC, Balser JR, George AL Jr, Benson DW. Clinical, genetic, and biophysical characterization of SCN5A mutations associated with atrioventricular conduction block. Circulation. 2002;105:341\u20136. PubMed PMID: 11804990.   \nWang H, Xu Z, Lee BH, Vu S, Hu L, Lee M, Bu D, Cao X, Hwang S, Yang Y, Zheng J, Lin Z.",
      "token_count": 482,
      "sentence_count": 28
    },
    {
      "id": "arvd_txt_9",
      "contents": "Molecular genetic testing is recommended in individuals who both fulfll diagnostic criteria as well as those with suspected arrhythmogenic right ventricular cardiomyopathy (ARVC) to (1) confrm the diagnosis of ARVC, as identifcation of an ARVC-related pathogenic variant is a major diagnostic criteria in the 2010 Task Force Criteria [Marcus et al 2010]; (2) guide management in those with more than one ARVC-related pathogenic variant identifed [Towbin et al 2019, James et al 2021]; and (3) enable testing of at-risk relatives (see Genetic Risk Assessment and Surveillance for Cardiac Involvement). \nNote: American College of Cardiology / American Heart Association / Heart Rhythm Society (AHA/ACC/HRS) guideline for management of ventricular arrhythmias and prevention of sudden cardiac death recommend genetic counseling and molecular genetic testing for individuals with clinically diagnosed or suspected ARVC as a class IIa recommendation (i.e., a moderate level of evidence supports the recommendation is reasonable, can be useful/efective/benefcial, and the benefts outweigh the risks) [Al-Khatib et al 2018]. \nEstablishing the specifc genetic cause of ARVC usually involves an evaluation with a cardiologist including medical history, physical examination, cardiology assessment, family history, and molecular genetic testing. Note: Molecular genetic testing should begin with a proband with a clinical diagnosis of ARVC or suspected ARVC rather than an unafected family member; molecular testing of an afected individual will provide the most informative results [James et al 2021]. \nMedical Evaluation \nMedical history and physical examination are directed at identifying physical features associated with spe cifc genetic causes of ARVC (Table 1). \nCardiology evaluation includes imaging to visualize the right ventricle, stress testing, and telemetric cardiac rhythm monitoring, as dictated by personal and family history. \nFamily history should include a three-generation family history with attention to heart palpitations, syncope, and sudden death in relatives; and documentation of relevant fndings through direct examination or review of medical records, including results of molecular genetic testing, cardiovascular and physical examinations, and postmortem examination.",
      "token_count": 472,
      "sentence_count": 9
    },
    {
      "id": "isselbacher-et-al-2022-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the_txt_123",
      "contents": " Use of electrocardiographic-synchronized CT techniques should be considered when there is a need to accurately depict mediastinal structures (eg, proximal aorta, coronary ostia). When IMH is present, the extent and thickness of the hematoma can be documented and, when PAUs are present, the presence of and size of pseudoaneurysms can be easily defined. \n\n2. In general, the choice of the initial imaging modality should be based on the patient\u2019s history and clinical presentation, the specific clinical questions to be answered, and the institutional availability, experience, and expertise with each of the diagnostic imaging techniques.6 In certain clinical circumstances, for example, patients with a history of an iodinated contrast reaction or patients who are too unstable to travel to the radiology suite, CT may not be preferred. Echocardiography (TEE/ TTE) is an alternative. TTE is noninvasive, can be performed at the bedside, and may be helpful in eliciting the diagnosis of AAS and quickly identifying complications of AAS, such as AR or pericardial effusion and tamponade. TEE is preferred to TTE, however, because of its higher sensitivity and better anatomic resolution; TEE can be performed at the bedside in the emergency department or, alternatively, once the patient is in the operating room. MRI is most commonly the third-choice modality, given that it is not readily available, requires skilled interpretation, and has longer acquisition times, as well as the fact it is challenging to provide clinical care to potentially unstable patients while in an MRI scanner. Consequently, MRI is most often used as a follow-up imaging modality in patients in which there is diagnostic uncertainty. Nevertheless, MRI may be the study of choice in the acute setting for a stable patient with a contraindication to iodinated contrast. \n\n7.3. Medical Management of AAS \nSynopsis \nPatients presenting with AAS need to be treated promptly to prevent acute and chronic complications. In all patients with AAS, immediate medical therapy is indicated while considering urgent surgical (in patients with type A aortic dissection), endovascular intervention (in patients with type B aortic dissection), or both; medical therapy includes aggressive heart rate and BP management as well as pain control.",
      "token_count": 480,
      "sentence_count": 13
    },
    {
      "id": "rws_txt_39",
      "contents": " PubMed PMID: 30753398.   \nSchwartz PJ, Priori SG, Cerrone M, Spazzolini C, Odero A, Napolitano C, Bloise R, De Ferrari GM, Klersy C, Moss AJ, Zareba W, Robinson JL, Hall WJ, Brink PA, Toivonen L, Epstein AE, Li C, Hu D. Lef cardiac sympathetic denervation in the management of high-risk patients afected by the long-QT syndrome. Circulation. 2004;109:1826\u201333. PubMed PMID: 15051644.   \nSchwartz PJ, Priori SG, Napolitano C. How really rare are rare diseases? J Cardiovasc Electrophysiol. 2003;14:1120\u20131. PubMed PMID: 14521668.   \nSchwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink P, Wilde AA, Toivonen L, Zareba W, Robinson JL, Timothy KW, Corfeld V, Wattanasirichaigoon D, Corbett C, Haverkamp W, Schulze-Bahr E, Lehmann MH, Schwartz K, Coumel P, Bloise R. Genotype-phenotype correlation in the long-QT syndrome: gene-specifc triggers for life-threatening arrhythmias. Circulation. 2001;103:89\u201395. PubMed PMID: 11136691.   \nSchwartz PJ, Spazzolini C, Crotti L. All LQT3 patients need an ICD: true or false? Heart Rhythm. 2009;6:113\u2013 20. PubMed PMID: 19121811.   \nSeth R, Moss AJ, McNitt S, Zareba W, Andrews ML, Qi M, Robinson JL, Goldenberg I, Ackerman MJ, Benhorin J, Kaufman ES, Locati EH, Napolitano C, Priori SG, Schwartz PJ, Towbin JA, Vincent GM, Zhang L. Long QT syndrome and pregnancy. J Am Coll Cardiol. 2007;49:1092\u20138.",
      "token_count": 488,
      "sentence_count": 25
    },
    {
      "id": "rws_txt_7",
      "contents": "stablishing a specifc genetic cause of long QT syndrome (LQ \u2022 Can aid in discussions of prognosis (which are beyond the scope of this GeneReview) and genetic counseling; \u2022 Usually involves a medical history, physical examination, family history, and genomic/genetic testing. \n\nClinical history. Clinical history in individuals with syncope or a cardiac arrest can reveal specifc triggers for the cardiac event that can be gene specifc. On rare occasions LQTS is accompanied by gene-spe cifc extracardiac features. \nPhysical examination. Te great majority of individuals with LQTS do not have associated physical features. On rare occasions, LQTS is accompanied by gene-specifc extracardiac features. Individuals with EKG characteristics suggestive of a specifc LQTS-associated syndrome (e.g., EKG with T-U patterns characteristic of Andersen-Tawil syndrome) can be assessed for physical features of that syndrome. \nFamily history. A three-generation family history should be taken, with attention to relatives with manifestations of LQTS \u2013 including syncope, aborted cardiac arrest, or sudden death in a child or (young) adult \u2013 and documentation of relevant fndings through direct examination or review of medical records, including results of molecular genetic testing and EKG recordings. Specifc focus should also be on triggers of events in relatives, as well as epilepsy (LQTS-associated syncopes may have been attributed to epilepsy). In such instances, review of medical records should include EEG recordings, accompanied by an EKG, which can show QTc prolongation in afected family members. \nEKG evaluation. Te corrected QT (QTc) values on resting EKG and ST-T wave morphology can suggest a specifc genetic cause of LQTS (see Table 2). Additional tests can be helpful to unmask QTc prolongation in individuals with borderline QTc values on resting EKG [Priori et al 2013]: \n\u2022 Exercise EKG, which commonly shows failure of the QTc to shorten normally and even prolongation of the QTc interval [Jervell & Lange-Nielsen 1957, Vincent et al 1991, Swan et al 1998, Horner et al 2011, Sy et al 2011].",
      "token_count": 484,
      "sentence_count": 17
    },
    {
      "id": "arvd_txt_1",
      "contents": "Note: Tere is a movement within clinical cardiology to merge ARVC with other arrhythmogenic cardiomyopathies because the lef ventricle can become involved, or even become predominantly involved, especially in individuals with $D S P$ pathogenic variants; lef ventricular involvement has also been reported in individuals with variants in genes encoding other desmosomal proteins (e.g., DSC2) that were previously associated with ARVC. Te 2010 Task Force Criteria (see Diagnosis) are still used to establish a clinical diagnosis of ARVC [Marcus et al 2010], and these criteria do not incorporate other arrhythmogenic cardiomyopathies, leading to potential underdiagnosis. An international expert panel convened to reevaluate the diagnostic approach to arrhythmogenic cardiomyopathies and developed new criteria, the Padua Criteria [Corrado et al 2020]. Tere are ongoing studies to evaluate the proposed Padua Criteria in larger cohorts. Readers should be aware of the potential overlap/diferentiation between ARVC and other arrhythmogenic cardiomyopathies. \ndescribed stages of ARVC are the following [Te Riele et al 20 \n1. Te concealed phase is the earliest phase and is without electrical, structural, or histologic changes as typically seen in ARVC. If scar formation is present, it can be so minimal that it goes undetected by cardiac MRI. However, afected individuals might experience sustained ventricular arrhythmias, and there is a potential risk of sudden cardiac death.   \n2. An overt electrical disorder characterized by symptomatic arrhythmias including palpitations, syncope, and presyncope attributable to ventricular ectopy or sustained or nonsustained ventricular tachycardia   \n3. Right ventricular failure   \n4. A biventricular pump failure (resembling dilated cardiomyopathy) [Dalal et al 2006] \nCardiomyopathy in ARVC is not always isolatedto right ventricular involvement. Tere is evidence that the  lef ventricle can ofen become involved as well.",
      "token_count": 454,
      "sentence_count": 15
    },
    {
      "id": "cantu_txt_19",
      "contents": " J wave syndromes. Heart Rhythm.",
      "token_count": 8,
      "sentence_count": 2
    },
    {
      "id": "brugada_txt_1",
      "contents": "Brugada syndrome is characterized by cardiac conduction abnormalities (ST segment abnormalities in leads $\\mathrm{V}_{1}$ - $\\mathrm{V}_{3}$ on EKG and a high risk for ventricular arrhythmias) that can result in sudden death. Brugada syndrome presents primarily during adulthood, although age at diagnosis may range from infancy to late adulthood.  Te mean age of sudden death is approximately 40 years. Clinical presentations may also include sudden infant death syndrome (SIDS; death of a child during the frst year of life without an identifable cause) and sudden unexpected nocturnal death syndrome (SUNDS), a typical presentation in individuals from Southeast Asia. Other conduction defects can include frst-degree AV block, intraventricular conduction delay, right bundle branch block, and sick sinus syndrome. \nDiagnosis/testing \nTe diagnosis of Brugada syndrome is established clinically in an individual with characteristic EKG fndin gs and suggestive clinical history and/or family history. A molecular diagnosis can be established in an individual with characteristic features and identifcation of a heterozygous pathogenic variant in SCN5A or one of the additional 42 genes associated with Brugada syndrome. \nManagement \nTreatment of manifestations: Implantable cardioverter defbrillator (ICD) in individuals with a history of syncope or cardiac arrest; isoproterenol for electrical storms. During surgery and in the postsurgical recovery period persons with Brugada syndrome should be monitored by EKG. \nPrevention of primary manifestations: Quinidine ( $1{\\mathrm{-}}2\\ {\\mathrm{g}}$ daily). Treatment of asymptomatic individuals is controversial. \nSurveillance: EKG monitoring every one to two years for at-risk individuals with a family history of Brugada syndrome or who have a known pathogenic variant that can lead to Brugada syndrome. \n",
      "token_count": 414,
      "sentence_count": 13
    },
    {
      "id": "cvt_txt_36",
      "contents": "Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, DeSimone L, Coltorti F, Bloise R, Keegan R, Cruz Filho FE, Vignati G, Benatar A, DeLogu A. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106:69\u201374. PubMed PMID: 12093772.   \nPriori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, Blom N, Brugada J, Chiang CE, Huikuri H, Kannankeril P, Krahn A, Leenhardt A, Moss A, Schwartz PJ, Shimizu W, Tomaselli G, Tracy C. HRS/EHRA/ APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013a;10:1932\u201363. PubMed PMID: 24011539.   \nPriori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, Blom N, Brugada J, Chiang CE, Huikuri H, Kannankeril P, Krahn A, Leenhardt A, Moss A, Schwartz PJ, Shimizu W, Tomaselli G, Tracy C, et al. Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace. 2013b;15:1389\u2013406. PubMed PMID: 23994779.   \nRahbari R, Wuster A, Lindsay SJ, Hardwick RJ, Alexandrov LB, Turki SA, Dominiczak A, Morris A, Porteous D, Smith B, Stratton MR, Hurles ME, et al. Timing, rates and spectra of human germline mutation. Nat Genet. 2016;48:126\u201333. PubMed PMID: 26656846.   \n",
      "token_count": 459,
      "sentence_count": 18
    },
    {
      "id": "brugada_txt_31",
      "contents": " PubMed PMID: 32248082.   \nMaury P, Couderc P, Delay M, Boveda S, Brugada J. Electrical storm in Brugada syndrome successfully treated using isoprenaline. Europace. 2004;6:130\u20133. PubMed PMID: 15018871.   \nMeregalli PG, Tan HL, Probst V, Koopmann TT, Tanck MW, Bhuiyan ZA, Sacher F, Kyndt F, Schott JJ, Albuisson J, Mabo P, Bezzina CR, Le Marec H, Wilde AA. Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies. Heart Rhythm. 2009;6:341\u20138. PubMed PMID: 19251209.   \nMills AT, Dasan S, Wan A. Brugada syndrome: syncope in the younger patient and the risk of sudden cardiac death. Emerg Med J. 2005;22:604\u20136. PubMed PMID: 16046779.   \nMiyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol. 1996;27:1061\u2013 70. PubMed PMID: 8609322.   \nMorita H, Kusano KF, Miura D, Nagase S, Nakamura K, Morita ST, Ohe T, Zipes DP, Wu J. Fragmented QRS as a marker of conduction abnormality and a predictor of prognosis of Brugada syndrome. Circulation. 2008;118:1697\u2013704. PubMed PMID: 18838563.   \nMorita H, Zipes DP, Wu J. Brugada syndrome: insights of ST elevation, arrhythmogenicity, and risk stratifcatio n from experimental observations. Heart Rhythm. 2009;6:S34\u201343. PubMed PMID: 19880072.   \nNakazato Y, Suzuki T, Yasuda M, Daida H.",
      "token_count": 470,
      "sentence_count": 31
    },
    {
      "id": "rws_txt_41",
      "contents": "Sy RW, van der Werf C, Chattha IS, Chockalingam P, Adler A, Healey JS, Perrin M, Gollob MH, Skanes AC, Yee R, Gula LJ, Leong-Sit P, Viskin S, Klein GJ, Wilde AA, Krahn AD. Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probands. Circulation. 2011;124:2187\u201394. PubMed PMID: 22042885.   \nTardo DT, Peck M, Subbiah RN, Vandenberg JI, Hill AP. Te diagnostic role of T wave morphology biomarkers in congenital and acquired long QT syndrome: a systematic review. Ann Noninvasive Electrocardiol. 2023;28:e13015. PubMed PMID: 36345173.   \nTester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm. 2005;2:507\u201317.",
      "token_count": 241,
      "sentence_count": 14
    }
  ],
  "scan_analyses": [
    {
      "scan_type": "ECG",
      "scan_date": "2025-03-24T21:51:25.290300",
      "file_name": "norm.png",
      "description": "ECG For Patient",
      "analysis": "Okay, let\u2019s analyze this ECG tracing. Here\u2019s a detailed breakdown of what I see, incorporating observations and potential interpretations:\n\n**Overall Impression:**\n\nThe ECG appears to be of a patient with a sinus rhythm, but with some notable findings suggesting underlying cardiac pathology.  The rate is slightly elevated, and there\u2019s evidence of left ventricular hypertrophy (LVH). \n\n**Detailed Analysis:**\n\n1. **Rate:** The heart rate is approximately 90-100 bpm. It's slightly elevated, which could be due to a variety of factors.\n\n2. **Rhythm:** The rhythm is regular, indicating a consistent and coordinated heartbeat.  It's a sinus rhythm, meaning the electrical impulses are originating from the sinoatrial (SA) node, the heart's natural pacemaker.\n\n3. **P Waves:**\n   *   P waves are present and appear generally upright in leads I, II, aVL, V1, V2, V5, and V6. \n   *   The morphology of the P waves is somewhat rounded and not distinctly shaped, which could be indicative of underlying conduction abnormalities or other subtle issues.\n\n4. **PR Interval:**  The PR intervals are slightly prolonged, ranging between 0.22-0.26 seconds.  Prolonged PR intervals often suggest first-degree AV block, although it can be influenced by electrolyte imbalances or medications.\n\n5. **QRS Complexes:**\n   *   The QRS complexes are wide, ranging from 0.12-0.14 seconds. This is a significant finding.  Wide QRS complexes often indicate a delay in ventricular depolarization, which could be due to several reasons:\n        *   **Bundle Branch Block:** The morphology of the QRS complexes in leads V1 and V6 suggests a right bundle branch block (RBBB).  The Q waves are slurred, and the R wave in V6 is wider and less slurred than in V1.\n        *   **Ventricular Hypertrophy:** The wide QRS complexes could also be a consequence of left ventricular hypertrophy, which can distort the QRS waveform.\n        *   **Impulse Subtractive Pathology:**  Less commonly, it could be due to an impulse subtractive condition.\n\n6. **ST Segment and T Waves:**\n   *   **ST Segment:** The ST segments are generally isoelectric (flat) except for V4 and V5, where"
    }
  ],
  "medical_entities": {
    "HISTORY": [
      "1980-05-15",
      "headache"
    ],
    "DISEASE_DISORDER": [
      "headache",
      "cardiac pathology",
      "left ventricular hypertrophy",
      "LVH",
      "conduction abnormalities",
      "AV block",
      "electrolyte",
      "Bundle Branch Block",
      "right bundle branch block",
      "RBBB",
      "Ventricular Hypertrophy",
      "Impulse Subtractive Pathology"
    ],
    "DIAGNOSTIC_PROCEDURE": [
      "physical exam",
      "ECG",
      "rate",
      "Rate",
      "heart rate",
      "Rhythm",
      "rhythm",
      "heartbeat",
      "Waves",
      "leads I",
      "II",
      "VL",
      "PR Interval",
      "PR intervals",
      "PR",
      "QRS Complexes",
      "QRS complexes",
      "ventricular",
      "Q waves",
      "R wave",
      "ST Segment",
      "T Waves"
    ],
    "DATE": [
      "24",
      "2025",
      "-03-24",
      "21:51:25"
    ],
    "LAB_VALUE": [
      "sinus",
      "slightly elevated",
      "90-100 bpm",
      "elevated",
      "regular",
      "upright",
      "rounded",
      "shaped",
      "prolonged",
      "0.",
      ".",
      "seconds",
      "wide",
      "delay",
      "slurred",
      "wider",
      "isoelectric"
    ],
    "SIGN_SYMPTOM": [
      "rhythm",
      "P",
      "P waves",
      "depolarization",
      "S"
    ],
    "BIOLOGICAL_STRUCTURE": [
      "sino",
      "node",
      "1",
      "5",
      "6",
      "leads V1 and V6",
      "V6",
      "ST",
      "ST segments",
      "V4 and V5"
    ],
    "DETAILED_DESCRIPTION": [
      "atrial",
      "SA",
      ",",
      ", a",
      ", V",
      ", V2, V",
      ", and V",
      "first-degree",
      "1"
    ],
    "DISTANCE": [
      "22",
      "0",
      "26",
      "12",
      "14"
    ]
  },
  "analysis_date": "2025-03-25T16:45:10.805349",
  "created_at": "2025-03-25T16:45:10.805358"
}